News & Updates
Filter by Specialty:
Systemic therapies effective in melanoma of unknown primary
Patients with melanoma of unknown primary (MUP) benefit from novel therapies similarly as those with stage-matched melanoma of known cutaneous primary (cMKP) despite having less favourable baseline prognostic factors, reveals a study.
Systemic therapies effective in melanoma of unknown primary
08 Apr 2023
High marks for modified-release oral PDE4 inhibitor in moderate-to-severe psoriasis
The modified-release formulation of novel oral phosphodiesterase-4 (PDE4) inhibitor orismilast shows therapeutic potential in adults with moderate-to-severe psoriasis, with high rates of clinical response as compared with placebo, according to data from the phase IIb IASOS trial presented at AAD 2023.
High marks for modified-release oral PDE4 inhibitor in moderate-to-severe psoriasis
05 Apr 2023
Oral JAK inhibitor makes headway in alopecia areata
Patients with severe alopecia areata (patchy baldness) had a dramatic hair regrowth, without serious adverse events, when treated with an investigational Janus kinase (JAK) inhibitor in the phase III THRIVE-AA2 study presented at AAD 2023.